Rahul Banerjee: Optimal MRD-based Endpoint in Multiple Myeloma
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, shared a post on X about recent article by Luciano J Costa, Smit Giri et al.:
“As usual, masterfully written (no pun intended) by Luciano J Costa, Smit Giri et al.
sMRD- at 10^-5 performed better than sMRD- at 10^-6. Turned many heads at ASH24. May be small n, or:
Maybe sMRD ≤10^-5 catches the most patients and gives us the prognostic info we need!”
Title: Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma
Authors: Smith Giri, Binod Dhakal, Natalie Callander, Eva Medvedova, Kelly Godby, Bhagirathbhai Dholaria, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca Silbermann, Luciano Costa.
More posts featuring Rahul Banerjee on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023